Analysis of PTEN and HIF‐1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon‐α

Publisher Website
Google Scholar
Abstract
BACKGROUND: Exploratory subgroup analyses from the phase 3 global advanced renal cell carcinoma (ARCC) trial were conducted to determine if baseline levels of the tumor molecular markers PTEN and HIF1 α correlated with efficacy in patients treated with temsirolimus (Torisel) versus interferon‐α (IFN). METHODS: Patients in the IFN group received 3 million U (MU) subcutaneously 3x weekly, escalating to 18 MU. Patients in the temsirolimus group received 25 mg intravenously weekly. PTEN and HIF1 α baseline levels were measured in archived tumor specimens by immunohistochemistry. RESULTS: There was no correlation between baseline PTEN and HIF1 α levels and treatment effect with respect to overall survival (OS), progression‐free survival, or objective response rate (ORR) in patients with advanced renal cell carcinoma with poor‐risk prognostic factors. CONCLUSIONS: The baseline status of the molecular markers PTEN and HIF1 α did not correlate with efficacy in renal cell carcinoma patients treated with temsirolimus versus IFN. Patients demonstrated OS and progression‐free survival benefit when treated with temsirolimus regardless of PTEN and HIF1 α status. Thus, baseline PTEN and HIF‐1 levels may not predict response to temsirolimus. Alternatively, the lack of correlation may be due to the variability in tumor specimens that occurred because of the global nature of the clinical trial. Other markers in the phosphoinositide 3‐kinase (PI3K)/Akt pathway may be of utility as predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Cancer 2009. © 2009 American Cancer Society.

This publication has 33 references indexed in Scilit: